Literature DB >> 21455713

TOMM40 poly-T variants and cerebrospinal fluid amyloid beta levels in the elderly.

Nunzio Pomara1, Davide Bruno, Jay J Nierenberg, John J Sidtis, Frank T Martiniuk, Pankaj D Mehta, Henrik Zetterberg, Kaj Blennow.   

Abstract

A variable poly-T polymorphism in the TOMM40 gene, which is in linkage disequilibrium with APOE, was recently implicated with increased risk and earlier onset age for late-onset Alzheimer's disease in APOE ε3 carriers. To elucidate potential neurobiological mechanisms underlying this association, we compared the effect of TOMM40 poly-T variants to the effect of APOE, an established LOAD-risk modulator, on cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau levels, in cognitively intact elderly subjects. APOE ε4 carriers showed significant reductions in Aβ 1-42 levels compared to non-ε4 carriers, but no differences were detected across TOMM40 variants. Neither Aβ 1-40 nor tau levels were affected by APOE or TOMM40.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455713      PMCID: PMC4550701          DOI: 10.1007/s11064-011-0459-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  15 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

Review 2.  Alzheimer's disease.

Authors:  Kaj Blennow; Mony J de Leon; Henrik Zetterberg
Journal:  Lancet       Date:  2006-07-29       Impact factor: 79.321

3.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

4.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

5.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

Authors:  A D Roses; M W Lutz; H Amrine-Madsen; A M Saunders; D G Crenshaw; S S Sundseth; M J Huentelman; K A Welsh-Bohmer; E M Reiman
Journal:  Pharmacogenomics J       Date:  2009-12-22       Impact factor: 3.550

6.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

Authors:  K Blennow; A Wallin; H Agren; C Spenger; J Siegfried; E Vanmechelen
Journal:  Mol Chem Neuropathol       Date:  1995-12

7.  Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Authors:  John S K Kauwe; Jun Wang; Kevin Mayo; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Neurogenetics       Date:  2008-09-24       Impact factor: 2.660

8.  Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Authors:  Mi-Ryung Han; Gerard D Schellenberg; Li-San Wang
Journal:  BMC Neurol       Date:  2010-10-08       Impact factor: 2.474

9.  Tom40, the import channel of the mitochondrial outer membrane, plays an active role in sorting imported proteins.

Authors:  Kipros Gabriel; Billie Egan; Trevor Lithgow
Journal:  EMBO J       Date:  2003-05-15       Impact factor: 11.598

10.  Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Authors:  Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman
Journal:  EMBO Mol Med       Date:  2009-11       Impact factor: 12.137

View more
  9 in total

1.  Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.

Authors:  Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow
Journal:  Exp Gerontol       Date:  2011-10-01       Impact factor: 4.032

Review 2.  The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.

Authors:  Ornit Chiba-Falek; William K Gottschalk; Michael W Lutz
Journal:  Alzheimers Dement       Date:  2018-03-07       Impact factor: 21.566

3.  Alzheimer disease: 'generation next' in Alzheimer disease genetic studies.

Authors:  Liana G Apostolova
Journal:  Nat Rev Neurol       Date:  2013-07-16       Impact factor: 42.937

4.  Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease.

Authors:  Cynthia M Stonnington; Brian Harel; Dona E C Locke; Joseph G Hentz; Nan Zhang; Paul Maruff; Richard J Caselli
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Oct-Dec       Impact factor: 2.703

Review 5.  APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.

Authors:  Andrew B Wolf; Richard J Caselli; Eric M Reiman; Jon Valla
Journal:  Neurobiol Aging       Date:  2012-11-16       Impact factor: 4.673

6.  The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial.

Authors:  Miles Berger; Jacob W Nadler; Allan Friedman; David L McDonagh; Ellen R Bennett; Mary Cooter; Wenjing Qi; Daniel T Laskowitz; Vikram Ponnusamy; Mark F Newman; Leslie M Shaw; David S Warner; Joseph P Mathew; Michael L James
Journal:  J Alzheimers Dis       Date:  2016-04-15       Impact factor: 4.472

7.  Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients.

Authors:  Michal Prendecki; Jolanta Florczak-Wyspianska; Marta Kowalska; Jan Ilkowski; Teresa Grzelak; Katarzyna Bialas; Malgorzata Wiszniewska; Wojciech Kozubski; Jolanta Dorszewska
Journal:  Oncotarget       Date:  2018-10-16

8.  Comprehensive search for Alzheimer disease susceptibility loci in the APOE region.

Authors:  Gyungah Jun; Badri N Vardarajan; Jacqueline Buros; Chang-En Yu; Michele V Hawk; Beth A Dombroski; Paul K Crane; Eric B Larson; Richard Mayeux; Jonathan L Haines; Kathryn L Lunetta; Margaret A Pericak-Vance; Gerard D Schellenberg; Lindsay A Farrer
Journal:  Arch Neurol       Date:  2012-10

9.  The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age.

Authors:  Beata Ferencz; Erika J Laukka; Martin Lövdén; Grégoria Kalpouzos; Lina Keller; Caroline Graff; Lars-Olof Wahlund; Laura Fratiglioni; Lars Bäckman
Journal:  Front Hum Neurosci       Date:  2013-05-22       Impact factor: 3.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.